Pembro benefits in mTNBC regardless of chemo typeDecember 16, 2020Breast CancerMetastatic Breast Cancer
First-in-class ADC has benefit across mTNBC subgroupsDecember 14, 2020Breast CancerMetastatic Breast Cancer
CTCs predict overall survival in metastatic breast cancerDecember 9, 2020Breast CancerMetastatic Breast Cancer
Should CTCs guide treatment choice in HR+, HER2– breast cancer?December 3, 2020Breast CancerMetastatic Breast Cancer
Pembrolizumab approved for triple-negative breast cancerNovember 16, 2020Breast CancerMetastatic Breast Cancer
Divergent findings with paclitaxel and nab-paclitaxel in TNBCSeptember 28, 2020Breast CancerMetastatic Breast Cancer
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020Breast CancerMetastatic Breast Cancer
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 resultsSeptember 9, 2020Breast CancerMetastatic Breast Cancer
First guideline on NGS testing in cancer, from ESMOAugust 28, 2020Breast CancerMetastatic Breast Cancer
Novel SERD, LSZ102, shows promise for pretreated ER+ breast cancerJune 30, 2020Breast CancerMetastatic Breast Cancer
Key Studies in Metastatic Breast Cancer From ASCO 2020June 22, 2020Breast CancerMetastatic Breast Cancer
‘A good and peaceful death’: Cancer hospice during the pandemicJune 5, 2020Breast CancerMetastatic Breast Cancer
